公司简介
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an an...
关联新闻
- Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.
- US FDA approves Replimune's skin cancer drug
The U.S. Food and Drug Administration has approved Replimune's drug for a difficult-to-treat form of skin cancer, the company said on Thursday, giving the biotech firm its first marketed product af...
- FDA Approves Replimune's Melanoma Drug On Third Attempt
The agency had turned down two earlier applications over clinical data-quality concerns.